Clin2
NCT06071767Possibly a fitSuspended

Immune therapy trial for early-treated HIV

HIV-1-infection

Treatments studied

Part of Infections clinical trials.

This study tests whether a combination of three immune therapies can help control HIV without daily medication. You may qualify if you started HIV treatment very early and have had a suppressed viral load for at least a year.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
36 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You started HIV treatment within 90 days of being diagnosed.
  • You have been on HIV treatment for at least 12 months with no breaks longer than 28 days.
  • Your viral load has been undetectable for at least a year, and your CD4 count is 450 or higher.
  • You are willing to temporarily stop your HIV medications under close monitoring and restart if needed.
  • You are not pregnant or breastfeeding, and you agree to use effective birth control if you could become pregnant.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07081763Not yet recruiting· Phase 2
Immune therapy for stopping HIV treatment safely

This trial tests if two drugs, baricitinib and sirolimus, can help control HIV after stopping standard antiretroviral therapy (ART). It aims to see if these immune treatments allow patients to maintain viral suppression without daily pills.

NCT06987318Not yet recruiting· Phase 1
Antibody therapy during a break in HIV treatment

This trial tests two lab-made antibodies that may help control HIV without daily pills. It is for people who started HIV treatment very early and now take a break from their regular meds under close monitoring.

Birmingham, Alabama
NCT07596888Recruiting· Phase 1
Early safety study of experimental HIV treatment IAP-086-1

This is an early-stage trial testing a new experimental drug (IAP-086-1) in people with HIV who have their virus well-controlled on current medications. Researchers want to understand how safe the drug is and how the body handles it.

Chapel Hill, North Carolina
NCT07054931Recruiting· Phase 2
Combination HIV vaccine and antibody therapy study

This trial tests a combination of an HIV vaccine and a new antibody treatment (GS-2872) to see if it can help control HIV without daily pills. It is for people with well-controlled HIV who are looking for ways to reduce their dependence on antiretroviral therapy.

London
NCT06484335Recruiting· Phase 1
Testing an HIV vaccine and antibody combo for treatment-free control

This study tests a combination of an HIV vaccine and an antibody infusion to see if your immune system can control HIV without daily pills. You would temporarily stop your HIV medication under close monitoring and restart if needed.

Pathum Wan, Bangkok
NCT05719441Recruiting· Phase 2
Antibodies plus early HIV treatment to try for HIV remission

This study tests whether giving special HIV-fighting antibodies along with starting standard HIV medicine soon after infection can help you reach “HIV remission.” It may reduce or delay the return of detectable virus, but you must be willing to follow close monitoring and specific study steps.

Birmingham, Alabama

Hear when a new HIV-1-infection trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.